NEW YORK (GenomeWeb) – Horizon Discovery said this week that an unnamed top-10 pharmaceutical firm has contracted the Horizon CombinatoRx division to profile a lead oncology asset. The contract is for six months and Horizon CombinatoRx will be paid $450,000 for its work, which includes services in support of proof of concept, monotherapy screening, and combination screening.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.